The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://aadamwuby766170.ourcodeblog.com/42205802/retatrutide-and-nad-a-integrated-approach-to-metabolic-wellness